山德士公司的AN 448（马吲哚）用于治疗肥胖症。
AN 448 Sandoz (Mazindol) in the treatment of obesity.
作者信息
Wallace A G
出版信息
Med J Aust. 1976 Mar 13;1(11):343-5.
PMID:775265
Abstract
The clinical value of a new anorectic agent, AN 448 Sandoz (mazindol) has been assessed in a double-blind trial against placebo in 50 obese patients. Over the 12 weeks of the trial, mazindol was shown to be an effective adjunct to carbohydrate restriction in weight reduction.
摘要
一种新型食欲抑制剂——山德士AN 448（马吲哚）的临床价值，已在一项针对50名肥胖患者进行的与安慰剂对照的双盲试验中得到评估。在为期12周的试验中，马吲哚被证明是限制碳水化合物摄入以减轻体重的有效辅助药物。
Zotero 插件